Literature DB >> 29871823

Microtubule-Targeting Agents: Strategies To Hijack the Cytoskeleton.

Michel O Steinmetz1, Andrea E Prota2.   

Abstract

Microtubule-targeting agents (MTAs) such as paclitaxel and the vinca alkaloids are among the most important medical weapons available to combat cancer. MTAs interfere with intracellular transport, inhibit eukaryotic cell proliferation, and promote cell death by suppressing microtubule dynamics. Recent advances in the structural analysis of MTAs have enabled the extensive characterization of their interactions with microtubules and their building block tubulin. We review here our current knowledge on the molecular mechanisms used by MTAs to hijack the microtubule cytoskeleton, and discuss dual inhibitors that target both kinases and microtubules. We further formulate some outstanding questions related to MTA structural biology and present possible routes for future investigations of this fascinating class of antimitotic agents.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  microtubule-targeting agents; molecular mechanisms of action; tubulin-ligand binding modes

Mesh:

Substances:

Year:  2018        PMID: 29871823     DOI: 10.1016/j.tcb.2018.05.001

Source DB:  PubMed          Journal:  Trends Cell Biol        ISSN: 0962-8924            Impact factor:   20.808


  76 in total

Review 1.  Targeting and extending the eukaryotic druggable genome with natural products: cytoskeletal targets of natural products.

Authors:  April L Risinger; Lin Du
Journal:  Nat Prod Rep       Date:  2019-11-25       Impact factor: 13.423

2.  Tubulin colchicine site binding agent LL01 displays potent antitumor efficiency both in vitro and in vivo with suitable drug-like properties.

Authors:  Jing-De Wu; Ying-Jie Cui; Yi-Gang Zhou; Long-Qian Tang; Cheng-Mei Zhang; Zhao-Peng Liu
Journal:  Invest New Drugs       Date:  2019-03-18       Impact factor: 3.850

Review 3.  Bioactive Compounds from Marine Heterobranchs.

Authors:  Conxita Avila; Carlos Angulo-Preckler
Journal:  Mar Drugs       Date:  2020-12-21       Impact factor: 5.118

4.  Unravelling the covalent binding of zampanolide and taccalonolide AJ to a minimalist representation of a human microtubule.

Authors:  Pedro A Sánchez-Murcia; Alberto Mills; Álvaro Cortés-Cabrera; Federico Gago
Journal:  J Comput Aided Mol Des       Date:  2019-05-31       Impact factor: 3.686

5.  A CTG repeat-selective chemical screen identifies microtubule inhibitors as selective modulators of toxic CUG RNA levels.

Authors:  Kaalak Reddy; Jana R Jenquin; Ona L McConnell; John D Cleary; Jared I Richardson; Belinda S Pinto; Maja C Haerle; Elizabeth Delgado; Lori Planco; Masayuki Nakamori; Eric T Wang; J Andrew Berglund
Journal:  Proc Natl Acad Sci U S A       Date:  2019-09-30       Impact factor: 11.205

6.  Prodrug Activation by a Viral Protease: Evaluating Combretastatin Peptide Hybrids To Selectively Target Infected Cells.

Authors:  Michael Richter; Mila M Leuthold; Dominik Graf; Ralf Bartenschlager; Christian D Klein
Journal:  ACS Med Chem Lett       Date:  2019-07-18       Impact factor: 4.345

7.  VISAGE Reveals a Targetable Mitotic Spindle Vulnerability in Cancer Cells.

Authors:  Jesse C Patterson; Brian A Joughin; Andrea E Prota; Tobias Mühlethaler; Oliver H Jonas; Matthew A Whitman; Shohreh Varmeh; Sen Chen; Steven P Balk; Michel O Steinmetz; Douglas A Lauffenburger; Michael B Yaffe
Journal:  Cell Syst       Date:  2019-07-10       Impact factor: 10.304

8.  Ultra-potent vinblastine analogues improve on-target activity of the parent microtubulin-targeting compound.

Authors:  Aleksandar Radakovic; Dale L Boger
Journal:  Bioorg Med Chem Lett       Date:  2019-03-26       Impact factor: 2.823

9.  Genetically encoded live-cell sensor for tyrosinated microtubules.

Authors:  Shubham Kesarwani; Prakash Lama; Anchal Chandra; P Purushotam Reddy; A S Jijumon; Satish Bodakuntla; Balaji M Rao; Carsten Janke; Ranabir Das; Minhajuddin Sirajuddin
Journal:  J Cell Biol       Date:  2020-10-05       Impact factor: 10.539

Review 10.  Stepping forward in antibody-drug conjugate development.

Authors:  Yiming Jin; Megan A Schladetsch; Xueting Huang; Marcy J Balunas; Andrew J Wiemer
Journal:  Pharmacol Ther       Date:  2021-06-24       Impact factor: 12.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.